Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $528000.0.

  • Pulmonx's Change in Accured Expenses fell 2786.89% to $528000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 26970.66%. This contributed to the annual value of $462000.0 for FY2024, which is 8545.34% down from last year.
  • Per Pulmonx's latest filing, its Change in Accured Expenses stood at $528000.0 for Q3 2025, which was down 2786.89% from $2.5 million recorded in Q2 2025.
  • Pulmonx's 5-year Change in Accured Expenses high stood at $4.0 million for Q4 2024, and its period low was -$6.0 million during Q1 2024.
  • Over the past 5 years, Pulmonx's median Change in Accured Expenses value was $1.0 million (recorded in 2022), while the average stood at $355315.8.
  • As far as peak fluctuations go, Pulmonx's Change in Accured Expenses surged by 23732.19% in 2021, and later crashed by 35753.42% in 2022.
  • Quarter analysis of 5 years shows Pulmonx's Change in Accured Expenses stood at $1.5 million in 2021, then soared by 58.05% to $2.4 million in 2022, then decreased by 5.53% to $2.3 million in 2023, then skyrocketed by 76.48% to $4.0 million in 2024, then plummeted by 86.72% to $528000.0 in 2025.
  • Its Change in Accured Expenses stands at $528000.0 for Q3 2025, versus $2.5 million for Q2 2025 and -$4.9 million for Q1 2025.